Sign In
Buy SAVA
$1.96
+0 (+0%)
At Close: Jun 03, 2026
Stay Far Away From Cassava Sciences Amid Data Integrity Criticisms
02:40pm, Friday, 29'th Apr 2022
Serious allegations have been made against Cassava by multiple sources, making SAVA stock far too risky for investors at this point. The post Stay Far Away From Cassava Sciences Amid Data Integrity Cr
Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know
09:50pm, Thursday, 28'th Apr 2022 Zacks Investment Research
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $20.90, marking a -0.99% move from the previous day.
Take Full Advantage of Weakness in Cassava Sciences Stock
03:03pm, Tuesday, 26'th Apr 2022
Cassava could run back to $40 again. Should the company get a positive nod for its Alzheimer's treatment, it could see $140 again.
Cassava Sciences Is a Worthwhile Bet to Consider
03:11pm, Monday, 25'th Apr 2022
FDA approval for Simufilam and successful trials of a new blood test to detect Alzheimer's disease could help propel SAVA stock back up. The post Cassava Sciences Is a Worthwhile Bet to Consider appea
The Crowd Has Wisely Soured on Cassava Sciences Stock
06:02pm, Wednesday, 20'th Apr 2022
As perceptions rise that its flagship drug candidate won't make it to market, steer clear of SAVA stock. The post The Crowd Has Wisely Soured on Cassava Sciences Stock appeared first on InvestorPlace.
Fresh Crop of Concerns Surrounding Alzheimer's Drug Sinks SAVA
10:19am, Tuesday, 19'th Apr 2022
The shares of Cassava Sciences Inc (NASDAQ:SAVA) are taking a drubbing this morning, last seen down 23.6% at $19.35, and set for their lowest open since January 2021.
New York Times Report Fresh Allegations On Cassava's Simufilam Alzheimer's Trials, Shares Fall
10:17am, Tuesday, 19'th Apr 2022
Cassava Sciences Inc (NASDAQ: SAVA) shares are shedding over 20% after The New York Times detailed new allegations related to the studies of the company's experimental Alzheimer's therapy, simufila
Why Is Cassava Sciences (SAVA) Stock Down Today?
09:47am, Tuesday, 19'th Apr 2022
SAVA stock is tumbling after The New York Times reported that multiple experts are skeptical about Cassava's data and its main theory. The post Why Is Cassava Sciences (SAVA) Stock Down Today?
Cassava Sciences Is Worth Considering After Hitting Its Latest Trough
05:04pm, Monday, 11'th Apr 2022
The company has no debt and is cash rich. If it receives FDA approval for its Simufilam drug, the SAVA stock price will catapult.
Biogen (BIIB) Down as Medicare Limits Coverage for Aduhelm
12:59pm, Friday, 08'th Apr 2022 Zacks Investment Research
Biogen (BIIB) stock declines after Medicare limits coverage for FDA-approved Alzheimer's drugs like Aduhelm only for patients enrolled in CMS-approved studies.
3 Key Points To Remember About Cassava Sciences
02:19pm, Thursday, 07'th Apr 2022
Cassava Sciences is trading near its 52 week lows.
Why Is Cassava Sciences (SAVA) Stock Down Today?
01:15pm, Tuesday, 05'th Apr 2022
Cassava Sciences (SAVA) stock is falling on Tuesday as investors react to a recent fireside chat held by CEO Remi Barbier. The post Why Is Cassava Sciences (SAVA) Stock Down Today?
Cassava Sciences, Inc. (SAVA) Outpaces Stock Market Gains: What You Should Know
10:00pm, Monday, 04'th Apr 2022 Zacks Investment Research
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $38.47, moving +1.37% from the previous trading session.
Webcast Details for Cassava Sciences’ Upcoming Fireside Chat
01:00pm, Monday, 04'th Apr 2022 GlobeNewswire Inc.
– All Stakeholder Are Welcome to Listen by Webcast –
Webcast Details for Cassava Sciences' Upcoming Fireside Chat
09:00am, Monday, 04'th Apr 2022
– All Stakeholder Are Welcome to Listen by Webcast –
